You are here

Article info

Article menu
Download PDFPDF
PostScript
Letter
Vedolizumab safety in pregnancy and newborn outcomes

Authors

  1. Correspondence to Professor Daniel C Baumgart, Inflammatory Bowel Disease Center, Charité Medical Center, Virchow Hospital, Medical School of the Humboldt University, Berlin D-13344, Germany; daniel.baumgart{at}charite.de
View Full Text

Citation

Julsgaard M, Kjeldsen J, Baumgart DC
Vedolizumab safety in pregnancy and newborn outcomes
Gut 2017;66:1866-1867.

Publication history

  • Received November 21, 2016
  • Revised December 10, 2016
  • Accepted December 17, 2016
  • First published January 10, 2017.
Online issue publication 
December 15, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/